1. Home
  2. JSPR vs GRDX Comparison

JSPR vs GRDX Comparison

Compare JSPR & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

SELL

Current Price

$14.35

Market Cap

26.3M

Sector

Health Care

ML Signal

SELL

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$3.20

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JSPR
GRDX
Founded
2018
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
28.6M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
JSPR
GRDX
Price
$14.35
$3.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 321.1K
120.2K
Earning Date
11-27-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
19.22
★ 21.95
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$1.87
52 Week High
$17.03
$6.93

Technical Indicators

Market Signals
Indicator
JSPR
GRDX
Relative Strength Index (RSI) 80.68 34.14
Support Level $0.64 $2.35
Resistance Level $17.03 $4.19
Average True Range (ATR) 1.05 0.78
MACD 1.15 -0.23
Stochastic Oscillator 79.63 0.35

Price Performance

Historical Comparison
JSPR
GRDX

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: